Antioxidant status of blood plasma of acutely psychotic patients and its correlation with Nrf2 activation

Proskurnina E.V.; Sokolova S.V.; Ershova E.S.; Martynov A.V.; Portnova G.V.; Kostyuk S.V.; Zakharova N.V.; Kostyuk G.P.

doi:https://doi.org/10.17116/jnevro202112102160

Proskurnina E.V.

Research Centre of Medical Genetics

Sokolova S.V.

Lomonosov Moscow State University, Medical Research and Educational Center

Ershova E.S.

Bochkov Research Centre for Medical Genetics

Martynov A.V.

Bochkov Research Centre for Medical Genetics

Portnova G.V.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences

Kostyuk S.V.

Bochkov Research Centre for Medical Genetics

Zakharova N.V.

Alekseev Moscow Psychiatric Hospital No. 1

Kostyuk G.P.

Alekseev Psychiatric Clinical Hospital No. 1

SPIN RSCI: 3424-4544
Scopus AuthorID: 57200081884
ORCID: 0000-0002-3073-6305

Antioxidant status of blood plasma of acutely psychotic patients and its correlation with Nrf2 activation

Authors:

Proskurnina E.V., Sokolova S.V., Ershova E.S., Martynov A.V., Portnova G.V., Kostyuk S.V., Zakharova N.V., Kostyuk G.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(2): 60‑66

DOI: 10.17116/jnevro202112102160

Read: 2309 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Proskurnina EV, Sokolova SV, Ershova ES, et al. . Antioxidant status of blood plasma of acutely psychotic patients and its correlation with Nrf2 activation. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(2):60‑66. (In Russ.)
https://doi.org/10.17116/jnevro202112102160

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the correlation between the blood plasma antioxidant profile and the transcriptional activity of the Nrf2 gene in acute psychosis in patients with schizophrenia and alcoholism.

MATERIAL AND METHODS

The study included 40 patients with the first episode of the paranoid form of schizophrenia, 33 patients with schizophrenic psychosis who had previously received therapy, 22 patients with first-time acute alcohol psychosis, and 25 healthy volunteers. The level of Nrf2 in peripheral blood mononuclear cells was estimated by flow cytometry, and the antioxidant profile of blood plasma was estimated with chemiluminometry.

RESULTS

The total and «thiol» antioxidant capacity were reduced in patients with initially diagnosed schizophrenic psychosis and alcoholic psychosis. In patients after treatment, the total antioxidant capacity was higher compared to previously untreated patients. The level of Nrf2 protein in mononuclear cells in patients with the first psychotic episode was significantly lower than in patients with alcoholism and lower than in the control group. In patients with alcoholic psychosis, Nrf2 level was correlated with both the total antioxidant capacity due to uric acid and the «thiol» antioxidant capacity; in patients with psychosis in schizophrenia, Nrf2 level was correlated only with the «thiol» antioxidant capacity.

CONCLUSIONS

The correlation between the total and «thiol» antioxidant capacity and the level of Nrf2 in mononuclear cells of patients with alcohol delirium indicates the undamaged state of the regulation. The absence of a correlation between the total antioxidant capacity and the level of Nrf2 in patients with schizophrenia indicates a disturbance of the activation of the Nrf2 pathway due to, possibly, a part associated with the participation of uric acid.

Keywords:

antioxidant status

oxidative stress

Nrf2

schizophrenia

alcoholism

Authors:

Proskurnina E.V.

Research Centre of Medical Genetics

Sokolova S.V.

Lomonosov Moscow State University, Medical Research and Educational Center

Ershova E.S.

Bochkov Research Centre for Medical Genetics

Martynov A.V.

Bochkov Research Centre for Medical Genetics

Portnova G.V.

Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences

Kostyuk S.V.

Bochkov Research Centre for Medical Genetics

Zakharova N.V.

Alekseev Moscow Psychiatric Hospital No. 1

Kostyuk G.P.

Alekseev Psychiatric Clinical Hospital No. 1

SPIN RSCI: 3424-4544
Scopus AuthorID: 57200081884
ORCID: 0000-0002-3073-6305

Received:

02.04.2020

Accepted:

22.07.2020

Close metadata

References:

Gonzalez-Blanco L, Garcia-Portilla MP, Garcia-Alvarez L, et al. Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Rev Psiquiatr Salud Ment. 2018;11:130–140. https://doi.org/10.1016/j.rpsm.2018.03.003
Bai ZL, Li XS, Chen GY, et al. Serum Oxidative Stress Marker Levels in Unmedicated and Medicated Patients with Schizophrenia. J Mol Neurosci. 2018;66:428–436. https://doi.org/10.1007/s12031-018-1165-4
Nishioka N, Arnold SE. Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2004;12(2):167–175.
Jorgensen A, Broedbaek K, Fink-Jensen A, et al. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Res. 2013;209:417–423. https://doi.org/10.1016/j.psychres.2013.01.033
Sertan Copoglu U, Virit O, Hanifi Kokacya M, et al. Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients. Psychiatry Res. 2015;229:200–205. https://doi.org/10.1016/j.psychres.2015.07.036
Magalhaes PV, Dean O, Andreazza AC, et al. Antioxidant treatments for schizophrenia. Cochrane Database Syst Rev. 2016;2:CD008919. https://doi.org/10.1002/14651858.CD008919.pub2
Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–114. https://doi.org/10.1016/j.jad.2015.04.044
Upthegrove R, Khandaker GM. Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia. Curr Top Behav Neurosci. 2019. https://doi.org/10.1007/7854_2018_88
Trepanier MO, Hopperton KE, Mizrahi R, et al. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry. 2016;21:1009–1026. https://doi.org/10.1038/mp.2016.90
Howes OD, McCutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 2017;7:e1024. https://doi.org/10.1038/tp.2016.278
Lee EE, Hong S, Martin AS, et al. Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables. Am J Geriatr Psychiatry. 2017;25:50–61. https://doi.org/10.1016/j.jagp.2016.09.009
Muller N. Neuroprogression in Schizophrenia and Psychotic Disorders: The Possible Role of Inflammation. Mod Trends Pharmacopsychiatry. 2017;31:1–9. https://doi.org/10.1159/000470802
Muller N. Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations. Schizophr Bull. 2018;44(5):973–982. https://doi.org/10.1093/schbul/sby024
Genc K, Genc S. Oxidative stress and dysregulated Nrf2 activation in the pathogenesis of schizophrenia. Bioscience Hypotheses. 2009;2:16–18.
Sandberg M, Patil J, D’Angelo B, et al. NRF2-regulation in brain health and disease: implication of cerebral inflammation. Neuropharmacology. 2014;79:298–306. https://doi.org/10.1016/j.neuropharm.2013.11.004
Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019;18:295–317. https://doi.org/10.1038/s41573-018-0008-x
Zhang L, Jin YP. Toxic effects of combined treatment of 1,2-dichloroethane and ethanol on mouse brain and the related mechanisms. J Biochem Mol Toxicol. 2019;33:e22294. https://doi.org/10.1002/jbt.22294
Huang MC, Chen CC, Pan CH, Chen CH. Comparison of oxidative DNA damage between alcohol-dependent patients with and without delirium tremens. Alcohol Clin Exp Res. 2014;38(10):2523–2528. https://doi.org/10.1111/acer.12539
Sueblinvong V, Mills ST, Neujahr DC, et al. Nuclear Thioredoxin-1 Overexpression Attenuates Alcohol-Mediated Nrf2 Signaling and Lung Fibrosis. Alcohol Clin Exp Res. 2016;40:1846–1856. https://doi.org/10.1111/acer.13148
Kumar A, Singh CK, Lavoie HA, et al. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol Pharmacol. 2011;80:446–457. https://doi.org/10.1124/mol.111.071126
Zheng J, Tian X, Zhang W, et al. Protective Effects of Fucoxanthin against Alcoholic Liver Injury by Activation of Nrf2-Mediated Antioxidant Defense and Inhibition of TLR4-Mediated Inflammation. Mar Drugs. 2019;17(10):552. https://doi.org/10.3390/md17100552
Dalton TP, Chen Y, Schneider SN, et al. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic Biol Med. 2004;37:1511–1526. https://doi.org/10.1016/j.freeradbiomed.2004.06.040
Cortese-Krott MM, Suschek CV, Wetzel W, et al. Nitric oxide-mediated protection of endothelial cells from hydrogen peroxide is mediated by intracellular zinc and glutathione. Am J Physiol Cell Physiol. 2009;296:811–820. https://doi.org/10.1152/ajpcell.00643.2008
Burton NC, Kensler TW, Guilarte TR. In vivo modulation of the Parkinsonian phenotype by Nrf2. Neurotoxicology. 2006;27:1094–1100. https://doi.org/10.1016/j.neuro.2006.07.019
Kostyuk SV, Porokhovnik LN, Ershova ES, et al. Changes of KEAP1/NRF2 and IKB/NF-kappaB Expression Levels Induced by Cell-Free DNA in Different Cell Types. Oxid Med Cell Longev. 2018;2018:1052413. https://doi.org/10.1155/2018/1052413
Ya BL, Liu Q, Li HF, et al. Uric Acid Protects against Focal Cerebral Ischemia/Reperfusion-Induced Oxidative Stress via Activating Nrf2 and Regulating Neurotrophic Factor Expression. Oxid Med Cell Longev. 2018;2018:6069150. https://doi.org/10.1155/2018/6069150
Huang TT, Hao DL, Wu BN, et al. Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem Biophys Res Commun. 2017;493:1443–1449. https://doi.org/10.1016/j.bbrc.2017.10.004
Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. 2017;298:210–224. https://doi.org/10.1016/j.expneurol.2017.06.017
Gultekin BK, Kesebir S, Kabak SG, et al. Are Uric Acid Levels Different from Healthy Subjects in Bipolar Affective Disorder and Schizophrenia? Relationship Between Clinical Improvement and Episode Severity in Male Patients. Noro Psikiyatr Ars. 2014;51:229–232. https://doi.org/10.4274/npa.y6827